<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4805">
  <stage>Registered</stage>
  <submitdate>28/01/2014</submitdate>
  <approvaldate>28/01/2014</approvaldate>
  <nctid>NCT02049138</nctid>
  <trial_identification>
    <studytitle>An Open-label Extension Study Evaluating the Safety and Efficacy of ABT-494 in Rheumatoid Arthritis Subjects</studytitle>
    <scientifictitle>Phase 2 Study, Multicenter, Open-Label Extension (OLE) Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial (RCT) With ABT-494</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2013-003530-33</secondaryid>
    <secondaryid>M13-538</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Rheumatoid Arthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ABT-494

Experimental: Open-label extension - All subjects will start treatment with ABT-494.


Treatment: drugs: ABT-494
Capsule

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>American College Rheumatology (ACR) 20 Response Rate - ACR criteria measures improvement in tender or swollen joint counts.</outcome>
      <timepoint>Up to Week 264</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>ACR 50 Response Rate - ACR criteria measures improvement in tender or swollen joint counts.</outcome>
      <timepoint>Up to Week 264</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>ACR 70 Response Rate - ACR criteria measures improvement in tender or swollen joint counts.</outcome>
      <timepoint>Up to Week 264</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in Tender Joint Count - Tender Joint Count will be assessed by a qualified Independent Joint Assessor or Principal Investigator using the Joint Evaluation Worksheet.</outcome>
      <timepoint>From Week 0 to Week 264</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in Swollen Joint Count - Swollen Joint Count will be assessed by a qualified Independent Joint Assessor or Principal Investigator using the Joint Evaluation Worksheet.</outcome>
      <timepoint>From Week 0 to Week 264</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in Patient's Assessment of Pain - Determined by the Joint Evaluation, Visual Analog Scale (VAS), EuroQoL-5D (EQ-5D)</outcome>
      <timepoint>From Week 0 to Week 264</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in Patient's Global Assessment of Disease Activity - Determined by VAS</outcome>
      <timepoint>From Week 0 to Week 264</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in High-Sensitivity C-Reactive Protein (hsCRP) - Determined by hsCRP lab test</outcome>
      <timepoint>From Week 0 to Week 264</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in Health Assessment Questionnaire Disability Index - Determined by the Health Assessment Questionnaire (HAQ-DI)</outcome>
      <timepoint>From Week 0 to Week 264</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Proportion of subjects achieving Low Disease Activity - Determined by disease activity score using 28 joint counts (DAS28) [CRP] or clinical disease activity index (CDAI) criteria</outcome>
      <timepoint>Up to Week 264</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Proportion of subjects achieving Clinical Remission - Determined by DAS28 [CRP] and CDAI criteria</outcome>
      <timepoint>Up to Week 264</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in DAS28 [CRP] - DAS28 [CRP] calculation</outcome>
      <timepoint>From Week 0 to Week 264</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in CDAI - The sum of tender and swollen joint counts [28 joints] and patient and physician global assessments</outcome>
      <timepoint>From Week 0 to Week 264</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Scale - Using the FACIT Fatigue Scale</outcome>
      <timepoint>From Week 0 to Week 264</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in Work Instability Scale - Rheumatoid Arthritis (RA-WIS) - Using RA-WIS scale</outcome>
      <timepoint>From Week 0 to Week 264</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in EQ-5D - Using the EuroQol-5D scale</outcome>
      <timepoint>From Week 0 to Week 264</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of Adverse Events</outcome>
      <timepoint>Up to 30 day follow-up visit (30 days after last dose of study drug)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in Vital Signs - Vital Signs include blood pressure, pulse rate, respiratory rate and body temperature</outcome>
      <timepoint>From Week 0 to 30 day follow-up visit (30 days after the last dose of study drug)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in Physical Examination - A symptom-directed physical exam will be performed when necessary, as per Investigator's judgment.</outcome>
      <timepoint>From Week 0 through 30 day follow-up visit (30 days after last dose of study drug)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in Clinical Laboratory Data - Clinical Laboratory Data include hematology, clinical chemistry and urinalysis</outcome>
      <timepoint>From Week 0 through 30 day follow-up visit (30 days after last dose of study drug)</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Subjects who have completed Study M13-550 or Study M13-537 with ABT-494 and has not
             developed any discontinuation criteria.

          2. If the subject has evidence of new latent Tuberculosis (TB) infection, the subject
             must initiate and complete a minimum of 2 weeks (or per local guidelines, whichever is
             longer) of an ongoing TB prophylaxis before continuing to receive study drug.

          3. If female, subject must meet one of the following criteria:

               -  Postmenopausal (defined as no menses for at least 1 year).

               -  Surgically sterile (bilateral oophorectomy or hysterectomy).

               -  Practicing from the time of screening until at least 30 days after the last dose
                  of study drug at least TWO of the following methods of birth control:

                    1. Tubal ligation

                    2. Partner vasectomy (at least 6 months earlier) (the vasectomized male partner
                       should be the sole partner for that female subject)

                    3. Intrauterine device

                    4. A male condom with spermicidal jelly or cream

                    5. Diaphragm, contraceptive sponge or cervical cap with spermicidal jelly or
                       cream

                    6. Hormonal contraceptives (injected, oral, transdermal or implanted methods)
                       must have been taking at least 2 months prior to dosing

          4. Male subjects must agree to follow protocol-specified pregnancy avoidance measures,
             including refraining from donating sperm, for up to 30 days post last dose of study
             drug.

          5. Subjects must voluntarily sign and date an informed consent, approved by an
             Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the
             initiation of any screening or study specific procedures.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Pregnant or breastfeeding female.

          2. Ongoing infections at Week 0 that have NOT been successfully treated. Subjects with
             ongoing infections undergoing treatment may be enrolled BUT NOT dosed until the
             infection has been successfully treated.

          3. Anticipated requirement or receipt of any live vaccine during study participation
             including up to 30 days after the last dose of study drug.

          4. Laboratory values from the visit immediately prior to Baseline Visit meeting the
             following criteria:

               -  Serum aspartate transaminase (AST) or alanine transaminase (ALT) &gt; 3.0 × Upper
                  Limit of Normal (ULN)

               -  Estimated glomerular filtration rate by simplified 4-variable Modification of
                  Diet in Renal Disease (MDRD) formula &lt; 40mL/min/1.73m2

               -  Total white blood cell count (WBC) &lt; 2,000/µL

               -  Absolute neutrophil count (ANC) &lt; 1,000/µL

               -  Platelet count &lt; 50,000/µL

               -  Absolute lymphocytes count &lt; 500/µL

               -  Hemoglobin &lt; 8 gm/dL

          5. Enrollment in another interventional clinical study while participating in this study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>24/01/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>494</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>20/02/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Idaho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>West Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Genk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Plovdiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Varna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Osorno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Puerto Varas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Bruntal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Hlucin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Ostrava-Trebovice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Prague 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Prague 4</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Uherske Hradiste</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szolnok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Veszprem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ashkelon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ramat Gan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Adazi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Baldone</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Riga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Ciudad de Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico D.F</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton, Waikato</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Nelson</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Timaru, South Canterbury</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Elblag</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdynia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Kracow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Nadarzyn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Nowa Sol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Oswiecim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kazan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Tver</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Martin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Senica</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Cape Town</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Stellenbosch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>A Coruna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Elche, Alicante</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Malaga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>San Sebastian de los Reyes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Santiago de Compostela</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Seville</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kiev</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bury St Edmunds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Warrington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase 2, multicenter, open-label extension study in RA subjects.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02049138</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Steven Pulaski, MD</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>